CA1254561A - 3-aminocarbonylmethoxy-5-phenylpyrazole compounds, method of their preparation and pharmaceutical compositions containing these compounds - Google Patents

Abstract

ABSTRACT OF THE DISCLOSURE
A process for preparing 3-(aminoalkylamino-carbonylmethoxy)-5-phenylpyrazole compounds correspond-ing to the formula:

Description

3-AMINOCARBONYLMETHOXY-5-PHENYI.PYRAZOLE COMPOUNDS, METHOD FOR THEIR P~EPARATION AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THESE COMPOUNDS
BACXGROUND OF THE INVENTION
This invention relates to new 3-(aminoalkylaminocarbonylmethoxy)-5-phenylpyrazole compounds and their salts and pharmaceutical com-positions containing these compounds, as well as methods for the preparation of these compounds.
3-hydroxycarbonylmethoxy-5-phenylpyrazole com-pounds and their esters and amides with blood lipid lowering properties have been described in the specifi-cation of European Patent Application No. 7019.

SUMMARY OF THE INVENTION
It is an object of the present invention to develop new 3-carbonylmethoxy-5-phenylpyrazole com-pounds with valuable pharmacological properties.
It has now been found that the new 5-phenylpyrazole compounds, substituted in position 3 by an aminoalkylaminocarbonyl radical, possess valuable pharmacological properties and distinguish themselves in particular by marked antiarrhythmic effects and an advantageous activity profile. Owing to their phar-macological effects, the new compounds are suitable as ~i~

~:~5a~
medicaments, particularly for the treatment and pro-phylaxis of heart rhythm disorders.
According to the present invention there are provided new 3-aminocarbonylmethoxy-5-phenylpyrazole compounds of the general Formula I

~ 0-C-C0-l-Z-N ~ 8 in which Rl is hydrogen or lower alkyl, R2 is in position 1 or 2 on the pyrazole ring and is hydrogen or lower alkyl, R3 is hydrogen, halogen, lower alkyl or lower alkoxy and R4 is hydrogen, halogen, lower alkyl, lower alkoxy or, if R3 is hydrogen, R4 may also be trifluoromethyl, nitro or hydroxy or R3 and R4 are linked to adjacent carbon atoms and toge~her represent an alkylene dioxy group with 1 or 2 carbon atoms, R5 is hydrogen or lower alkyl and R6 is hydrogen or methyl or R5 and R6 together form an alkylene chain with 3 to 5 carbon atoms, R7 is hydrogen or lower alkyl, z is an alkylene chain with 2 to 5 carbon atoms or the 2-hydroxypropylene chain, R8 is hydrogen or lower alkyl and Rg is hydrogen or lower alkyl or R8 and Rg together with the nitrogen atom to which they are linked represent a heterocyclic group of the general formula a -N A a in which A is an alkylene chain with 4 or 5 carbon atoms which chain may be substituted by 1 or 2 methyl groups, or A is the -C2H4-O-C2~-chain, or if Z is an alkylene chain, then R8 may be hydrogen or lower alkyl and Rg may be an alkylene chain, which together with the nitrogen atom to which it is linked and the carbon atom of the alkylene chain Z which is adjacent to this nitrogen atom, forms a 5- or 6-membered heterocycle;
and the acid addition salts of said components of the general formula I.
In the compounds of Formula I, where the substituent groups Rl to Rg represent or contain lower alkyl or al~oxy groups, these may be straight chain or branched groups with preferably 1 to 4 carbon atoms;
the lower alkyl group i5 more preferably a methyl or ethyl group.
Rl is preferably hydrogen, and if Rl is a lower alkyl group, this is preferably a methyl or ethyl group. R2 is preferably hydrogen, and if R2 is lower alkyl group, this is preferably the methyl group.
Of the substituent groups R3 and R4 on the phenyl ring, the preferred lower alkyl and alkoxy groups are methyl and methoxy groups, while the pre-ferred halogens are fluorine, chlorine, and bromine, most preferably fluorine. Preferably, R3 and/or R4 represent hydrogen or also fluorine, chlorine or methyl.
R5 is advantageously a lower alkyl group with 1 to 4, preferably 1 or 2 carbon atoms, which is pre-ferably a primary, straight-chained group. Preferably R5 and R6 are each methyl. If Rs contains at least 2 carbon atoms, R6 is preferably hydrogen. If Rs and R6 ~,.f~

together form an alkylene chain, this is preferably a propylene chain. Advantayeously Rs and R6 together contain 2 or 3 carbon atoms. R7 is preferably hydrogen and if R7 is an alkyl group, this is preferably hydro-gen and if R7 is an alkyl group, this is preferably aprimary alkyl group with 1 to 4, most preferably 1 or 2 carbon atoms.
If Z represents an alkylene chain, this is preferably a straight chain with 2 or ~ carbon atoms.
If R8 and/or Rg are/is lower alkyl, these may be straight or branched and contain 1 to 4, preferably 1 or 2 carbon atoms. Advantageously, at least one of the substituent groups R8 and Rg is a lower alkyl group or is part of a heterocyclic ring. Desirably, the -NRgRg group is a preferably unbranched dialkylamino group, particularly the diethylamino group. Examples of heterocyclic -rings formed from the radical Rg and the nitrogen atom, to which it is linked, together with the radical R8 or the C-atom of the al~ylene chain Z
adjacent to the nitrogën, include piperidine, morpho-line and pyrrolidine rings.
The new 3-aminocarbonylmethoxy-5-phenyl-pyrazole compounds of formula I and their acid addition salts are obtained according to the invention in that 5 in a manner known per se a) a compound of the general Formula II or III

~1 ~5 \ 0-C-C0-Y II
I

~5~

~ ¦ ~ .III

in which Rl, R2, R3, R4, Rs and R6 have the above defined meanings and Y i5 a reactive group, is reacted with a compound of .the general Formula VIII

X-N-Z-N ~ YIII
~ 9 ~7 in which R7, z, R8 and Rg have the above defined meanings, or b) a compound of the general Formula IV

~5 ~ -C-CO-I-Z-X~ IV

in which Rl, R2, R3, R4, ~5, R6, R7 and Z have the above defined meanings and Xl is a group which can be split of aminolytically, is reacted with an amino com-pound of the general Formula V

R~
Rg _5 _ in which R8 and ~9 have the above defined meanlngs, or c) a compound of the general Formula Vl ~ ~ 2 VI

in which Rl, R2 R3 and R4 have the above defined meanings, and/or a 5-phenylpyrazolin-3-one compound tautomeric therewith is reacted with a compound of the general Formula VII

¦5 / R8 Hal-C-CO-N-Z-~ VII
\~9 R6 n7-in which R5, R6, R7, Z, R8 and Rg have the above defined meanings and ~al is halogen, or d) or the preparation of a compound of the general Formula Ia R1 ~ ~ 8 -C-CO-N-CH-~H-C~ -N Ia R6 ~ ~H 2 ~ Rg ~4 in which Rl, R2, R3, R4 Rs, R6, R7, R8 and Rg have the above defined meanings, a compound of the general Formula IX

1~ ¦
R ~ ~ -l-co-l-cH2- ~ -5H IX

in which Rl, R2, R3, R4, R5, R6 and R7 have the above defined meanings, is reacted with a compound of the general Formula V
/ ~8 HN \ V
Rg If R4 in the resulting compound of the general Formula I is methoxy, the methoxy group is optionally split to form the hydroxy group. If the compound of formula I is obtained in the form of the free compound, it is optionally converted into an acid addition salt or if the compound of formula I is obtained in the form of an acid addition salt the salt is optionally con-verted into the free compound of Formula I.

DETAILED DESCRIPTION OF THE PREFERRED EMBOI)IMENTS
For carrying out t~e reaction according to process variant a), the acids or acid derivatives of Formula II or, insofar as compounds are concerned in which R2 is hydrogen, the cyclicized acid derivatives of Formula III or mixtures of compounds of Formulae Il and III may be used.

The reaction of the acid or acid derivative of Formulae II or III with the diamine of Formula VIII may be carried out by methods conver~tional Per se for the formation of amide groupings throuyh aminoacylation.
The compound of Formula II may be in the form of the acid (Y = OH) or a reactive derivative of the acid, in which Y is a reactive group, or a cyclic derivative of the acid of Formula III. Examples of reactive deriva-tives of formula II, include acid halides, preferably acid chlorides, esters, and mixed anhydrides, e.g., compounds ~f Formula II~ in which the reactive group Y
denotes halogen, preferably chlorine or bromine, lower alkoxy, preferably alkoxy with 1 to 4 carbon atoms, or a group O-W, in which W is a lower alkylcarbonyl or lower alkoxycarbonyl group or an organic sulphonic acid radical, particularly the radical of a lower alkane sulphonic acid, such as, for example, methane sulphonic acid or an aromatic sulphonic acid, such as benzene sulphonic acid or benzene sulphonic acids substituted by lower alkyl or halogen.
If an acid of~Formula II itselE is used, the reaction is advantageously carried out in the presence of a coupling reagent known to be suitable for amide formation. Suitable coupling reagents, which promote amide formation in that they react with the acid in situ with the formation of a reactive acid derivative, are known from peptide chemistry. The following may be mentioned as examples of suitable coupling reagents:
alkylcarbodiimides, preferably cycloalkylcarbodiimides such as dicyclohexylcarbodiimide, carbonyldiimidazole and N-lower alkyl-2-halopyridinium salts, particularly halides or tosylates, preferably N-methyl-2-chloropy-ridiniumiodide (see, for example, Mukaiyama in 'Angew.
Chemie' 91, pages 789 to 81~). The reaction in the presence of a coupling reagent may suitably be carried out at temperatures from -30C up to ambient tem-perature using solvents such as halogenated hydrocar-bons and/or aromatic solvents optionally in the presence of an acid-binding amide~
The preferred compounds of Formula II include esters or acid halides, particularly acid chlorides, or mixed acid anhydrides, particularly those obtained by the reaction of an acid of Formula II with an organic sulphonic acid chloride, such as methane sulphonic acid chloride, or mixed anhydrides obtained by reaction with an ester o~ chloroformic acid. Alternatively cyclic derivatives of Formula III may be used. The reaction of the amide with the acid halide, acid anhydride and/or with a cyclic derivative of Formula III is carried out in the presence of an inert organic solvent, for example, a halogenated hydrocarbon such as methylene chloride, a cyclic or open ether such as dioxane or diethyl ether, dimethylformamide, sulpho-lane, tetramethyl carbamide or mixtures of these solvents and, optionally aromatic hydrocarbons such as benzene or toluene. Insofar as acid halides or acid anhydrides of Formula II are used, it is desirable to carry out the reaction in the presence of an acid-binding agent. The following are suitable examples of acid-binding agents: inorganic bases, for example alkali metal carbonates or hydroxides, or organic bases, particularly tertiary lower alkylamines, e.g., triethylamine or pyridine. In place of an added base, an excess of the amine of Formula VIII may also be used. Organic bases used in excess may also serve, at the same time, as solvents. In addition, it may be advantageous to add catalytic quantities of basic pyri-dines such as 4-dimethylaminopyridine or 4 pyrrolidino-pyridine. Advantageously, the reaction is carried out at a temperature of from -30C to the boiling tem-perature of the reaction mixture. The selected tem-perature may vary depending upon the initial compounds used; for example, in using acid halides or acid anhydrides of Formula II and cyclic derivatives of Formula III, low temperatures of up to approximately ambient temperatures are preferred.
It is particularly advantageous to react an intensively cooled solution of the acid derivatives of formula II or III with a solution of the amine of Formula VIII. If the amine contains a second reactive amine function, it is desirable to gradually add the solution of the acid derivative to the amine solution.
If the starting material is a compound of Formula II, in which R2 is hydrogen, the compound may be partially converted, under the above~mentioned reac-tion conditions, into the corresponding cyclic compound of Formula III, which then further reacts with the amine of Formula VIII.
The reaction of compounds of Formula IV with amines of Formula V according to method variant b) may be carried out according to methods which are conven-tional per se in aminoalkylation. Suitable examples ofaminolytically replaceable radicals xl in the compounds of Formula IV include halogens such as chlorine, bro-mine and iodine, and organic sulphonic acid radicals, in particular radicals of lower alkyl sulphonic acids such as, for example, methane sulphonic acid or radi-cals of aromatic sulphonic acids, such as benzene sulphonic acid or benzene sulphonic acids substituted by lower alkyl or halogen, e.g., toluene sulphonic acids or bromobenzene sulphonic acids.
3~ Advantageously, reaction b) is carried out in an organic solvent which is inert under the Leaction conditions. Suitable solvents include aromatic hydro-carbons such as ben~ene, toluene or xylene, cyclic ethers such as dioxane, dimethylformamide, sulpholane, tetramethylcarbamide or dimethylsulphoxide.
Advantageously, an excess of the amine of Formula V is i6~

used as an acid-binding agent. ~n excess of the amine may also serve as solvent. I~ desired, inorganic bases may also be added as acid-binding agents. Sui~able inorganic bases include, for example, alkali metal car-bonates and bicarbGnates.
The reaction according to method variant c) represents an alkylation, known per se, at the oxygen atom in position 3 o~ the 3-hydroxypyrazole or of the pyrazolin-3-one tautomeric therewith. The reaction takes place advantageously under basic conditions in an inert solvent, for example, dimethylformamide, a cyclic ether such as dioxane, tetramethylcarbamide, dimethylsulphoxide, an aromatic hydrocarbon such as toluene or a mixture of two or more thereof. In orga-nic bases such as alkali metal carbonates or hydroxides are particularly suitable as basis. Advantageously, approximately equivalent quantities of the compound of Formula VI and of the inorganic base are used. If desired, the compound of Formula VII may also be reacted with an alkali metal salt of the compound of Formula VI which may be~ produced in situ through reac-tion of the compound of Formula VI in one of the above-mentioned solvents with an alkali metal hydride. The reaction preferably takes place at a temperature of from OC up to the boiling temperature of the solvent, preferably at a temperature of from O to 100C.
The reaction of a compound of Formula IX with a compound of ~ormula V according to method variant d) may take place in a manner conventional in the reaction of epoxides. Advantageously, the reaction is carried out in an organic solvent which is inert under the reaction conditions, at a temperature from approxima-tely OC to approximately 100C. The following are examples of suitable solvents: aromatic hydrocarbons such as benzene, toluene or xylene, open or cyclic ethers such as, for example, diethylether, tetrahydro-furan or dioxane, and lower alcohols.

~ ~5 ~ 6 ~

In compounds of Formula I, in which R4 is methoxy, the methoxy group may be split by methods suitable for the splitting of methoxyaryl ethers, in a manner known per se, to form a hydroxy group. For example, the ether decomposition may take place by treatment with hydrogen iodide in acetic anhydride or with lithium iodide in a pyridine, e.g., 2,4~6-tri-methylpyridine.
If the initial compounds contain free hydroxy groups, these may, if desired, be provided with a pro-tective group prior to the above reactions in a manner known per se, which group can easily be split off afterward. Suitable protective groups are known, for example, from E. McOmie "Protective Groups in Organic Chemistry" Plenum Press 1971. Hydrolytically or hydro-genolytically separable ethers such as tetrahydropyra-nyl ether or benzyl ether are suitable, for example, for the protection of a hydroxy group.
The compounds of formula I may be isolated from the reaction mixture, in a manner known per se, and purified. Acid addition salts may be converted into the free bases in a conventional manner and these may be converted, if desired, in a known manner into pharmacologically acceptable acid addition salts. The following are examples of suitable pharmacologically acceptable acid addition salts of compounds of Formula I: salts with inorganic acids such as hydrochloric acid, sulphuric acid and phosphoric acid, and salts with organic acids such as methane sulphonic acid, ethane sulphonic acid, cyclohexylaminosulphonic acid, aminosulphonic acid, acetic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, phenylacetic acid and mandelic acid. The starting compounds of Formulae II
and VI are known, or may be produced according to methods known as per se.
It is known that the compounds of Formula VI
exist in several tautomeric forms, and that in addition to the enol form of the 5 phenylpyrazole-3-ols repro-duced in Formula VI, the corresponding keto form of the 5-phenylpyrazoline-3-ones also exists. In general, mixtures oE the various tautomeric ~orms are present~
the composition of which may vary depending upon the nature of the substituent groups. Both forms, or their mixtures, may be used in preparing compounds of Formula I according to the invention. In the present specifi-cation, compounds of Formula VI therefore include all tautomeric forms of these compounds.
Compounds of Formula VI may be obtained by methods known per se for the production o~
5-phenylpyrazoline-3-ones through cyclizing conden-sation of optionally substituted hydrazines of Formula XII
NH -N~R XII

in which R2 has the above defined meaning, with benzoyl acetic acid esters of Formula XIII

R3 ~ Co-cH-cooc2H5 XIII

in which Rl, R3 and R4 have tbe above defined meanings, or with phenyl propiolic acid esters of Formula XIV

~IV

R

in which R3 and R4 have the above defined meanings.

The reaction takes place in an organic solvent which is inert under the reaction conditions, for example, a lower alkanol such as methanol or ethanol, an aromatic hydrocarbon, an open or cyclic ether or a halogenated S hydrocarbon. If ~2 is lower alkyl, there is produced by the reaction a mixture of isomeric compounds in which R2 is arranged in position 1 or 2. The ratio of l-alkyl to 2-alkyl compounds may vary depending upon the nature of the starting materials and the solvent which is used. Isomeric mixtures of 1- and 2-alkyl compounds may be separated in a manner known as per se by fractional crystallization or by chromatography.
Acids and esters of Formula II are known, for example, from published European Patent Application 7019, or they may be produced according to methods known Per se, for example, the methods described in the European Patent Application 7019.
Thus for the production of acids of Formula II, compounds of Formula VI may be reacted in a manner known per se with compounds of Formula XV

Hal- C -R10 XV

in which Rs, R6 and Hal have the above defined meanings and Rlo is lower alkoxy carbonyl or cyano, to form (5-phenylpyrazole-3-oxy)-acetic acid esters and ni-triles of Formula XVI
~5 -~6R1O XVI

~s~

in which Rl~ R2 r R3~ R4, Rs, ~6 and R1o have the above defined meanings, and these may be subsequently hydro-lysed. The reaction of the compounds of Formula VI
with the compounds of Formula XV may be carried out according to methods known per se for the alkyla~ion at the oxygen atom in position 3 of 5-phenyl-pyrazolin-3-ones under basic conditions, for example under the conditions indicated for method variant c). The reac-tion may suitably be performed in dimethylformamide in the presence of potassium carbonate. In general, esters of Formula XV are used. If Rs and R6 are both hydrogen, nitriles of Formula XV prove to be advan-tageous. Insofar as the phenyl ring possesses a free hydroxy substituent, it is desirable to provide it prior to the reaction, in a manner known E~ se, with a protective group which is easily removable afterward under conditions under which the ether group in posi-tion 3 of the pyrazole structure and the amide group in the side chain of the compounds of Formula I are not affected.
If desired, in compounds of Formula XVI in which R2 is hydrogen, an alkyl group R2 may be intro-duced in a manner known per se through alkylation under basic conditions.
Compounds of Formula XVI may be hydrolysed in a manner known per se to form the corresponding acids of Formula II and these may be converted in a manner known per se into further reactive acid derivatives.
The hydrolysis preferably takes place under alkaline conditions, for example by treatment with a~ueous alkali metal hydroxide solution, optionally in the presence of an organic solvent which is miscible with water. The conversion of the free acids into reactive 3~SB~5~

acid derivatives likewise takes place in a manner known ~er se. Thus acid halides of Formula II, for example may be obtained by reaction o~ the acids with an inorganic acid halide, for example thionyl chloride.
Optionally the reaction may be carried out in the presence of pyridine or another tertiary organic base.
Mixed acid anhydrides may be obtained for exarnple by reaction of the acid with an equivalent quantity of another acid chloride, for example a sulphonic acid chloride, such as methane sulphonic acid chloride, in the presence of an acid-binding agent, preferably a tertiary organic base, such as triethyl amine.
Compounds of Formula II in which R2 is hydro-gen may be partially condensed during the methods of preparation described above to form the corresponding cyclic compounds of Formula III, so that the resulting compounds of Formula II may contain varying quantities of compounds of Formula III as a by-product depending upon the reaction conditions. As compounds of Formulae II and III may be further reacted in the same manner with an amine, the sep~rating of any mixtures of com-pounds of Formula II and III into the individual com-pounds is unnecessary.
Pure compounds of Formula III may be obtained by the cyclizing condensation of the corresponding reactive acid derivatives of Formula II, particularly of mixed anhydrides of Formula II. The condensation takes place, for example, when the solution of a mixed anhydride of Formula II is left to stand at ambient temperature in an inert organic solvent, e.g., a halo-genated hydro¢arbon such as methylene chloride.
Compounds of the general Formula IV may be obtained in a manner known per _ from compounds of the general Formula II, by reacting them with amino alco-hols of Formula X

HN-z-OH
X

in which R7 has the above defined meaning, and sub-sequently converting the terminal hydroxy group in the side chain in the 3-position of the resulting product, in a manner known ~er se, into an aminolytically re-placable group Xl. The reaction of the compounds ofFormula II with the compounds of Formula X may take place under conditions which are conventional for amide formation, for example the conditions described above for the reaction of compounds of Formula II with com-pounds of Formula VIII. In the reaction, the desiredamide formation predominates. The terminal hydroxy group in the lateral chain of the resulting amide may be converted in a manner known per se into an aminoly-tically replaceable group, for example with a conven-tional halogenating agent, such as for example thionylchloride, phosphorus oxychloride or phosphorus tribro-mide, in order to obtain a compound of Formula IV, in which Xl is halogen. Alternatively, the terminal hydroxy group may be esterified according to methods known E~ se, for example, reacted with a corresponding acid halide, in order to obtain compounds of Formula IV, in which xl is a reactive acid radical, par-ticularly one of the above-mentioned sulphonic acid radicals. In these reactions, the terminal primary hydroxy group reacts predominantly beEore any secondary hydroxy group possibly contained in the substituent z.
For the production of compounds of Formula IV, in which xl is halogent the compounds of Formula II may also be reacted directly with the corresponding haloalkylamines Compounds of Formula VII may be produced in a manner known Per se by the reaction of corresponding -halocarboxylic acids or their reactive derivatives with diamines of Formula VIII under conventional con-ditions for amide formation.

5~

Compounds of Formula IX may be obtained by reaction compounds of Formula II, particularly acid chlorides of Formula II, with amines of Forrnula XI
HN-CH2 -CH_

2 X~

in which R7 has the above defined meaning, in a manner known per se.
The compounds of Formula I and their pharma-cologically acceptable acid addition salts have interesting pharmacological properties, particularly heart rhythmizing effects. The new compounds are distinguished by marked antiarrhythmic effects with a favourable activity profile and good physiological com-patibility. In particular, the compounds display the property of raising the electrical stimulus threshold for eliciting rhythm disorders in the heart.
The doses to be used vary, of course, depending upon the nature of the compound administered, the manner of administration and the condition which is to be treated. In general, however, satisfactory results are obtained in tests on animals with doses of from 0.01 to 100 mg/kg body weight. Determination of the specific dose to be used in a given case is within the skill of the art.
The antiarrhythmic effects of the compounds can be shown in pharmacological test methods in animals.
1. Determination of protection from chloroform-induced ventricular fibrillation in mice.
The effect of the compounds on the ventricular fibrillation in mice brought about through chloroform inhalation leading to rapid respiratory arrest is determined according to Lawson's method (J. Pharmacol.
Exp. Ther. 160, 22-23).

In this test arrangement, the minimal toxic dose can also be determined at ~he same time. The test substances in 0.9% NaC1 solution are administered i.p.
to female mice with a body weight of from 17 to 24 g.
The animals are kept individually in qlass beakers, where they are observed for possible toxic symptoms.
Ten minutes after administration of the test substan-ces, the animals are transferred to covered 300 ml glass beakers which contain a swab of cotton wool soaked with approximately 20 ml chloroform. I-mmedi-ately after respiratory arrest has occurred, the ani-mals are removed from the glass beaker and heart rhythm and rate are observed. The percentage of animals is determined, which are protected from chamber fibrilla-tion by the dose of test substance which has been admi-nistered.
2. Determination of the electrical fibrilla-tion threshold of the right ventricle in the heart of a guinea-pig.
The capability~of- the substances to raise the electri~al stimulus threshold is determined on male albino Pirbright~white guinea-pigs with a body weight of from 250 to 450 g. The animals are narcotised by i.p. application of 1.50 g/kg urethane and are placed in a supine position on a thermal bench which is pro-vided with a thermostat. The test substances are admi-nistered via a cannula connected into a vein. Each animal receives a series of increasing doses. The electrocardiogram is taken with a bipolar conductance (subcutaneous needle electrodes on both sides of the thorax) and is observed on an oscilloscope. Via a bipolar suction electrode which is introduced into the right ventricle through the vena iuqularis, an intra-cardial stimulation is produced through a series of rec-tangular impulses (duration l ms, frequency 50 ~z,using a stimulator manufactured by the firm Hugo Sachs ~.25~

Elektronik). The current intensity is increased within 5 to 15 seconds up to occurrence of chamber fibrilla-tion. The current intensity (in ~A), at which chamber fibrillation is observed, is defined as the fibrilla-tion threshold of the right ventricle. T~e fibrilla-tion threshold of the individual animals is measured before application of the first dose and after each further dose o~ the test substance which is admin-istered. The dose which on average causes an increase in the fibrillation threshold by 50% is defined as ED150%-The results obtained by the test methods described above are shown in the following table. The Example numbers given for the compounds of Formula I
refer to the preparation Examples which follow.

~5~6~, Exa~rple I Minimal toxic j Inhibiting effect I Increase of .electrical No. Idose l~ikk ~espect to l.stimwlus threshold in the I mg/kg l.chloro~orm induced Iguine~-pig Imouse i.p. Icha~ber ~ib~ tionlED ~ .
I in mice ~ % protected 150 /~ l-V-I dose animals I ;~ol/kg ¦ m~kg l l 200 1 25 1 -~ 1 00 1 1 . 4

3 1 200 1 25 I . 67 1 0.~2 I l 9 1 200 1 50 1 33 1 2 . 6 16 1 200 1 50 1 100 1 3,0 18 1 100 1 10 1 100 1 0,78 1 1 1 . 1 1,2 I I l I
27 1 1 . I l 1,$
28 1 1 l l 200 30 1 200 1 25 1 67 1 1, 9 I
31 1 100 1 25 1 67 1 i.l ~8 1 200 1 50 1 1 00 1 3 . 0 I
40 1 100 1 25 1 100 1 0.75 41 1 200 1 25 1 100 1 1.5 55 1 >200 1 100 1 100 1 2,2 I -56 1 1 1 1 2,6 I
64 1 ~200 1 100 1 100 1 1,7 59 1 200 1 50 1 100 1 2.6 68 3 1 1 1 2,7 Because of their e~fects described above, the compounds of formula I and their pharmacologically acceptable acid addition salts are useful as medica-ments for the treatment and prophylaxis of heart rhythm disorders. They may be administered by conven-tional enternal and parenteral techniques.
The compounds of Formula I and their physiolo-gically compatible acid addition salts may be com-pounded, as medicines, With conventional pharmaceutical adjuvant substances in pharmaceutical preparations such as, for example, tablets, capsules, suppositories or solutions. These pharmaceutical preparations may be produced according to methods known per se using con-ventional solid carrier substances such as for example, lactose, starch or talcum, or liquid diluents such as for example water, fatty oils or liquid paraffins.
The invention will now be illustrated by the following non-limiting Examples which describe in further detail the production of new compounds of Formula I.
The structures-of the new compounds were con-firmed by spectroscopic examinations, in particular by analysis of the NMR-, mass-, IR- and/or W - spectra.
Example 1:
3-t2-(3-diethylaminopropylaminocarbonyl)-propyl-2-oxy]-5-phenylpyrazole.
A) 6.2 ml benzoyl acetic acid ethyl ester were mixed with 3.7 ml ethanol. 3.3 ml 80~ hydrazine hydrate were added to the solution dropwise under ice cooling and the reaction mixture was left to stand for 12 hours. The precipitated 5-phenylpyrazolin-3-one was then filtered off and first washed with a little etha-nol and then with diethyl ether. Melting point 236 to 240C; yield 5.5 g.

~s~

B) 5g 5 phenylpyrazolin-3-one were dissolved in 50 ml dimethyl formamide. 1.5 g of an approximately 50% oily sodium hydride preparation are added to the solution in portions. 15 minutes later, 5.7 ml 2-bromo-2-methylpropionic acid ethyl ester are added dropwise and the reaction mixture is stirred for 24 hours at a temperature of 80C. The solvent was then evaporated under reduced pressure and the remaining residue was suspended in methylene chloride. After filtering off the precipitated sodium bromide crystals, the solution was washed with water and the aqueous washing waters are extracted once again with methylene chloride. The combined methylene chloride phases were dried over magnesium sulphate and concentrated. The crude product which was obtained was purified by column chromatography over silica gel using hexane/ether mix-tures as elution agent. 4.9 g crystalline 3-(2-ethoxy-carbonylpropyl-2-oxy)-5-phenylpyrazole were obtained.
Melting point 79C.
C) 42 g 3-(2-ethoxycarbonylpropyl-2-oxy)-5-phenylpyrazole were dissolved in 200 ml ethanoll the solution was mixed with 103 ml 20% sodium hydroxide and the reaction mixture was heated under reflux to complete the reaction. The ethanol was largely distilled off and the remaining aqueous reaction mix-ture was acidified under ice cooling with 20% hydroch-loric acid until the pH was 1. The precipitated 3-(2-hydroxycarbonylpropyl-2-oxy)-5-phenylpyrazole was filtered off. Melting point 152 to 155C; yield:
36.5 g D) 493 mg 3-(2-hydroxycarbonylpropyl-2-oxy)-5-phenylpyrazole were suspended in 4 ml dry methylene chloride and mixed with 0.55 ml triethylamine. After 10 minutes the reaction mixture was cooled to -30C
bath temperature, and in order to form a mixed ~z~4s~

anhydride, 0.16 ml methane 5 ulphonic acid chloride was added dropwise and the mixture was stirred for a further hour at -30C. The react1on mixture containing the resulting 2-methyl-2-g~5-phenylpyrazol-3yl~-oxy~-propionic acid methane sulphonic acid anhydride wasimmediately used in the following reaction.
E) A spatula tip of 4-pyrrolidinopyridine was added to the reaction mixture produced under D) and containing the mixed anhydride, and subsequently 0.32 ml 3-diethylaminopropylamine was added dropwise and the reaction mixture was slowly heated to ambient temperature and stirred for a further 2.5 hours~ Then it was mixed with 5 ml methylene chloride and washed twice with dilute sodium carbonate solution. The orga-nic phase was separated off, dried and concentrated.
649 ms of the title compound remained as an oily base (IR spectrum (as film): 3220 cm~l, 1650 cm~l, 1530 cm~l). dissolved in acetone and converted into its hydrogen maleinate salt through the addition of a solu-tion of 232 mg maleic acid in acetone. 644.5 mg 3-12-~3-diethylaminopropylaminocarbonyl)-propyl-2-oxyl-5-phenyl-pyrazole-hydrogen maleinate were obtained;
melting point 135C.
Exam~le 2 3-~2-(3 diethylaminopropylaminocarbonyl)-propyl-2-oxy3-5-phenylpyrazole.
0.32 ml 3-diethylaminopropylamine was added dropwise to a reaction mixture produced in an analogous manner to Example lD and containing the mixed anhydride of 493 mg 3-t2-hydroxycarbonylpropyl-2-oxy3~5-phenyl-pyrazole and methane sulphonic acid, and the reaction mixture was slowly heated to ambient temperature and stirred for a further 2.5 hours. Then working up was carried out, as described in Example lE. 515 mg of the title compound are obtained as an oily base. This was converted into its hydrogen maleinate as described in Example lE. Melting point 135C.
Example 3 3-12-(3-diethylamino-2-hydroxypropylaminocarbonyl)-propyl-2-oxy~-5-phenylpyrazole~
A) 4.7 g 5-phenylpyrazolin-3-one and 4.1 g anhydrous potassium carbonate were suspended in 60 ml dimethyl formamide. The suspension was heated for approximately 10 minutes to 100C, then cooled to 60C
and mixed dropwise with 4.8 ml 2-bromo-2-methyl pro-pionic acid ethyl ester. The mixture was stirred for 4 hours at 100C and subsequently the solvent was eva-porated under reduced pressure and the residue was dissolved in 150 ml water. The aqueous solution was extracted twlce with 150 ml diethyl ether in each case and the organic phase was dried over magnesium sulphate and concentrated; 6.9 g crude 3-(2-etoxycarbonylpropyl-2-oxy)-5-phenylpyrazole-were obtained as an oil. This was crystallized from- ethyl acetate; melting point 78.5C. Subsequently the product was hydrolysed to 3-(2-hydroxycarbonylpropyl-2-oxy)-5-phenylpyrazole as described in Example lC.
~ ) 9.85 g 3-(2-hydroxycarbonylpropyl-2-oxy)-5-phenylpyrazole were reacted according to the method described in Example lD with methane sulphonic acid chloride to form the mixed anhydride and this was reacted in situ with 3-diethylamino-2-hydroxy-propylamine in an analogous manner to Example lE. The reaction was worked up as described in Example lE, and the resulting crude produce was chromatographed for further purification on a silica gel column using an ether/methanol mixture as elution agent. 10.5 9 of the title compound were obtained as an oily base. This was dissolved in acetone and converted into its hydrogen maleinate salt through the addition of a solution of 3.25 g maleic acid in acetone. 10.6 y 3-~3-di-ethylamino-2-hydroxypropylaminocarbonylpropyl~2-oxy3-5-phenylpyrazole hydrogen maleinate were obtained;
melting point 160.
Example 4 3-(2-aminoethylaminocarbonylpropyl-2-oxy)-5- phenyl-pyrazole.
8.6 9 3-(2-hydroxycarbonylpropyl-2-oxy)-5-phe-nylpyrazole were dissolved in 60 ml methylene chlorideand mixed with 9.7 ml triethylamine. After 10 minutes, the mixture was cooled to -30C bath temperature, and the mixture was mixed dropwise with 2.74 ml methane sulphonic acid chloride and stirred for a further hour at -30C. The solution containing the resulting mixed anhydride was transferred into a dropping funnel kept at a temperature of -30C and was added dropwise into 45 ml ethylene diamine~ over a period of 1.5 hours.
Subsequently the mixture was stirred for a further hour at ambient temperature to complete the reaction. The reaction mixture was then diluted with methylene chloride and washed with 20% sodium hydroxide solution.
The organic phase was dried and evaporated. The remaining crude produce was purified by chromatography on aluminum oxide using methylene chloride/methanol as the elution agent. For conversion into its hydrogen maleinate, the chromatographically purified titLe com-pound was dissolved in acetone and mixed with a solu-tion of 1.57 g maleic acid in acetone, and the solution was evaporated. The residue was taken up with water, the aqueous phase was extracted twice with ether and subsequently made alkaline by the addition of sodium carbonate solution, and the title base, released again from the maleinate, was extracted with ether. On eva-poration of the ether extract 1.7 g of the title com-pound were obtained and dissolved together with 1.1 g maleic acid in isopropanol. The solution was added dropwise into ether, whereby the 3-(2-aminoethyl-aminocarbonylpropyl-2-oxy)-5-phenylpyrazole hydrogen maleinate precipitated out. It was filtered off and washed with ether. Melting point 128 to 135C; yield 1.3 g.
Example 5 3-diethylaminoethylaminocarbonylmethoxy)-5-phenylpyrazole A) In an analogous manner to the method described in Example lB, 40 9 5-phenylpyrazolin-3-one in 120 ml dimethyl formamide were first deprotonated by reaction with 5.6 g of an 80% oily sodium hydride pre-paration and subsequently reacted with 11 ml chloroace-tonitrile to form 3-cyanomethoxy-5-phenylpyrazole.
Melting point: 143C.
B) 25.2 g 3-cyanomethoxy-5-phenylpyrazo]e were dissolved in 200 ml ethanol and mixed with 50 ml 20% sodium hydroxide solution. The reaction mixture was heated for one hour at reflux. After cooling, the mixture was acidified with 20% aqueous hydrochloric acid until the pH was 1. The precipitated 3-hydroxy-carbonylmethoxy-5-phenylpyrazole was filtered off.
Melting point: 193C; yield 22.3 g.
C) 4.36 9 3-hydroxycarbonylmethoxy-5-phe-nylpyrazole were converted into the mixed acid anhydride by reaction with methane sulphonic acid chloride, and this was reacted in situ with 2-diethyl-aminoethylamine in accordance with the method described in Example lD and E. The reaction mixture was worked up as described in Example lE. The resulting 3-(di-ethylaminoethylaminocarbonylmethoxy)-5-phenylpyrazole was crystallized from ethyl acetate. Melting point 100 to 101C; yield 4.6 g.
ExamPle 6 3-(2-morpholinoethylaminocarbonylmethoxy)-5-phenyl-pyrazole 1.33 ml N-(2-aminoethyl)-morpholine, 2.2 9 3-hydroxycarbonylmethoxy-5-phenylpyrazole and 4.3 ml triethylamine were added in this order to 3.06 9 1-methyl-2-chloropyridinium iodide in methylene chloride. The reaction mixture was then heated to boiling for 3 hours under reflux. After cooling and washing with aqueous sodium hydroxide solution, the organic phase was evaporated, and the crude product obtained was purified chromatographically. 2.3 9 3-(2-morpholinoethylaminocarbonylmethoxy)-5-phenyl-pyrazole were obtained as an oily base. IR-spectrum (as film): 3205 cm-l, 1660 cm~l.
Example 7 3-~2-(3-diethylaminopropylaminocarbonyl)-propyl-2-oxy~-5-(3,4-dichlorophenyl)-pyrazole 13.7 g 3-(2-ethoxycarbonylpropyl-2-oxy)-5-(3,4-dichlorophenyl)-pyrazole were added to 30 ml 3-diethylaminopropylamine and the reaction mixture was heated under nitrogen for 18 hours at 180C. On completion of the reaction, ex~ess amine was distilled off in vacuum. Then the crude title compound which was obtained was dried in a desiccator over concentrated sulphuric acid. 16.2 9 3-t2-(3-diethylaminopropyl-aminocarbonyl)-propyl-2-oxyl-5-(3,4-dichlorophenyl)-pyrazole remained as an oily base~ For further purification, the compound was dissolved in ether, and i6~

the etheral solu~ion was fil~ered over silica gel.
IR-spectrum (as film~: 322 cm-l' 1645 cm-l~ 1530 cm~l.
Example 8 3-t2-(3-morpholinopropylaminocarbonyl)-propyl-2-oxy~-5-phenylpyrazole 9 g 3-(2-hydroxycarbonylpropyl-2-oxy)-5-phe-nylpyrazole were dissolved in methylene chloride and 5.6 ml triethylamine were added dropwise under ice cooling. After stirring for 30 minutes, 3.6 ml ethyl choroformate were added dropwise and the reaction mix-ture was stirred for a further hour at aMbient tempera-ture. The reaction mixture containing the resulting 3-~2-ethoxycarbonyloxycarbonylpropyl-2-oxy)-5-phenylpy-razole was then added dropwise under ice cooling to a solution of 8 ml N-(3-aminopropyl)-morpholine in methy-lene chloride. The mixture was stirred for a further hour under ice cooling and for a further hour at ambient temperature, and was then washed with dilute sodium hydroxide solution. The organic phase was dried and evaporated, and the residue was dissolved in 75 ml ethanol. 35 ml 20% sodium hydroxide were added, and the mixture was heated for 3 hours under reflux. It was then reduced to half the volume, diluted with water and extracted witb methylene chloride. The crude pro-duct obtained from the methylene chloride phase waspurified by chromatography on silica gel using an ether/methanol mixture. 5.9 g 3t2-(3-morpholino-propylaminocarbonyl)-propyl-2-oxyl-5-phenylpyrazole were obtained as an oily base. IR-spectrum (as film3: ~3240 cm~l, 1650 cm~l, 1530 cm~l.

:~Z~ ;6~

Example 9 3-t2-(3-diethylaminopropyl~ninocarbonyl)-propyl-2-oxy3-l-methyl-5-phenylpyrazole A) 20.5 g methyl propionate were dissolved in 150 ml toluene and 6.7 ml methyl hydrazine were added to the solution under ice cooling. After standing for 12 hours, the solution was evaporated. The residue was a mixture of l-methyl-5-phenylpyrazolin-3-one and 2-methyl-5-phenylpyrazolin-3-one. This crude isomeric mix~ure was chromatographed on silica gel. Ether was used as elution agent, to which increasing quantities of methanol were added. From the eluate the non-polar l-methyl-5-phenylpyrazolin-3-one was isolated. Melting point: 160-161C; yield 6.3 g.
B) 4.5 g 1-methyl-5-phenylpyrazolin-3-one were reacted, as described in Example 3~, to form 3-(2-ethoxycarbonylpropyl-2-oxy)-1-methyl-5-phenylpy-razole, and this was further hydrolyzed without purifying to form 3-(2-hydroxycarbonylpropyl-2-oxy)-1-methyl-5-phenylpyrazole.
C) The crude 3-(2-hydroxycarbonylpropyl-2-oxy)-l-methyl-5-phenylpyrazole obtained above was converted as described in Example lD by reaction with methane sulphonic acid chloride into the mixed anhydride, and ~his was reacted with 3-diethylamin-opropylamine. The reaction mixture was worked up as described in Example lE, and the title compound was isolated as an oily base. IR-spectrum (as f ilm):
~ 3340 cm~l, 1668 cm 1, 1545 cm~l. The title com-pound was then converted into its hydrogen maleinate as described in Example lE. 3.27 g 3-12-~3-diethyl-aminopropylaminocarbonyl)-propyl-2-Oxy]-l-methyl-5-phenylpyrazole-hydrogen maleinate were obtained as an oil.

Example 10 3-t2-(3-diethylaminopropylaminocarbonyl)~propyl-2-oxy3-5-phenylpyrazole A) 2.3 g 3-(2-hydroxycarbonylpropyl-3-oxy)-5-phenylpyrazole (prepared as described in Example lC) were suspended in 50 ml dry methylene chloride and mixed with 2.6 ml triethylamine. After 10 minutes the reaction mixture was cooled to -30C bath temperature, and, in order to form a mixed anhydride according to the method described in Example lD, was mixed dropwise with 0.72 ml methane sulphonic acid chloride and stirred for a further hour at -30C. The reaction solution containing the mixed anhydride was then slowly heated to ambient temperature for the cyclizing condensation of the mixed anhydride to the corresponding 2,2-dimethyl-6-phenyl-pyrazolo-[5,1-bg oxazolin-3-one and was stirred at ambient temperature until the reaction was complete. Then the reaction mixture was washed with sodium carbonate solution the organic phase was separated off, dried and partly eva-porated. The resulting 2,2-dimethyl-6-phenyl-pyrazolo-55,1-b~-oxazolin-3-one was recrystallized from a mixture of ethyl acetate and diethyl ether. Melting point 110C.
B~ 230 mg 2,2-dimethyl-6-phenyl-pyrazolo-t5,1 b~-oxazolin-3-one and 0.16 ml 3-diethylamino-propyl~mine were dissolved in 1 ml dry tetrahydrofuran, and the solution was stirred under a nitrogen atmosphere at ambient temperature for approximately 50 hours. The solvent was evaporated under vacuum, and the residue was dissolved in diethyl ether. The solu-tion was washed with concentrated sodium carbonate solution, and the organic phase was separated off, dried and evaporated. 360 mg 3-~2-(3-diethylamino-~z~

propylaminocarbonyl)-propyl-2-oxy~-5-phenylpyrazole were obtained as an oily base. This was converted into its hydrogen maleinate as described in Example lE.
Melting point 135C.
ExamPle 11 3-~2-(3-diethylaminopropylaminocarbonyl~-propyl-2-oxy~-5-phenylpyrazole 230 mg 2,2-dimethyl-6-phenyl-pyrazolo-t5,1-b~-oxa201in-3-one (prepared as in Example lOA) were dissolved in approximately 2 ml 3-diethyl-aminopropylamine under nitrogen, and the solution was allowed to stand for 2 hours at ambient temperature.
Then the excess amine was distilled off in vacuum. The remaining crude title compound was dried in a desic-cator over concentrated sulphuric acid to remove basicimpurities. 360 mg 3-~2-(3-diethylaminopropylamino-carbonyl)-propyl-2-oxyl-5-phenylpyrazole were obtained as an oily base. This was converted into its hydrogen maleinate as described in Example lE. Melting point:
135C.
Example 12 3-t2-(2-morpholinoethylaminocarbonyl)-propyl-2-oxy] 2-methyl-5-phenylpyrazole A) 5 g 3-(2-hydroxycarbonylpropyl-2-oxy) 2-methyl-5-phenylpyrazole were suspended in 40 ml dry methylene chloride and mixed with 8.3 ml triethylamine.
After 10 minutes 1.48 ml methane sulphonic acid chloride were added dropwise, and the reaction mixture was stirred for a further 30 minutes. Then a spatula tip of 4-pyrrolidinopyridine was added to the reaction mixture containing the mixed anhydride, and subsequent-ly 3.9 g 2-bromoethylamine hydrobromide were added in ~s~

portions within 30 minutes. The reaction mixture was allowed to stand for 3 hours and was then washed first with aqueous citric acid solution and thereafter "ith sodium carbonate solution. The organic phase was dried and partly evaporated. As a residue 3~8 g 3-12-(2-bromoethylaminocarbonyl)-propyl-2-oxy3-2-methyl~5-phenylpyrazole were obtained. Melting point 130C.
B) 3~8 9 3-t2-(2-bromoethylaminocarbonyl)-propyl-2-oxy]-2-methyl-5-phenylpyrazole were dissolved in a little ethanol, and the solution was added drop-wise over a period of 2 hours into lO0 ml boiling morpholine. The reaction mixture was heated at reflux for a further 30 minutes and then concentrated in vacuum. The residue was taken up in methylene chloride and extracted with aqueous citric acid solution. The aqueous phase was separated, made allcaline by the addi-tion of sodium carbonate solution and extracted with ether. The ether phase was separated and evaporated.
The remaining residue was dried in a desiccator over sulphuric acid. The crude title compound thus obtained was purified through chromatography on silica gel.
2.8 g 3-12-(2-morpholinoethylaminocarbonyl)-propyl-2-oxy~-2-methyl-5-phenylpyrazole were obtained. Melting point 105C. IR-spectrum (in KBr): ~3340 cm~l 1670 cm~l, 15~5 -l.
ExamPle 13 3-t2-(3-diethylaminopropylaminocarbonyl)-propyl-2-oxy]
5-phenylpyrazole A) 3.4 g 2-b.omo-2-methylpropionic acid were added to 30 ml dry methylene chloride and mixed with 5.4 ml triethylamine. After 10 minutes the reaction mixture was cooled to -30C bath temperature, l.4 ml methane sulphonic acid chloride were added dropwise, and the mixture was stirred for a further hour at -30C

~.2~

to form a mixed anhydride. Then a spatula tip of

4-pyrrolidinopyridine was added, and 3.1 ml of 3-diethylaminopropylamine were a~ded dropwise, and the reaction mixture was slowly heated to ambient tem-perature and stirred at ambient temperature for afurther 2.5 hours. Then 40 ml methylene chloride were added, and the mixture was washed twice with dilute sodium carbonate solution. The organic phase was separated, dried and concentrated. 3 g N-(3-diethyl-aminopropyl~-2-bromo-2-methylpropionic acid amide were obtained as an oily base. IR-spectrum (as film): 3310 cm~l, 1660 cm~l, 1530 cm~l.
B~ 1.6 g 5-phenylpyrazolin-3-one and 2 g anhydrous potassium carbonate were suspended in 20 ml dimethylformamide. The suspension was heated for 10 minutes to 100C. Then it was cooled to 60C, and a solution of 3 9 N-(3-diethylaminopropyl)-2-bromo-2-methylpropionic acid amide in 10 ml dimethyl for-mamide was added dropwise to the mixture. The reaction mixture was stirred for 4 hours at 100C. Then the solvent was evaporate~ under reduced pressure, and the residue was dissolved in 50 ml water. The aqueous solution was extracted twice with 50 ml diethyl ether in each case. The combined ether extracts were dried over magnesium sulphate and concentrated. 0.9 g 3-12-(3-diethylaminopropylaminocarbonyl)-propyl-2-oxyl-

5-phenylpyra201e were obtained as an oily base.
IR-spectrum (as film): 3220 cm~l, 1650 cm~l, 1530 cm~l. The base was converted into its hydrogen maleinate as described in Example lE. Melting point 135C.

~25~

Example 14 3-~2-(3-diethylaminopropylaminocarbonyl)~propyl-2-oxy3-5-(4-hydroxyphenyl)-pyrazole 160 mg 3-12-(3-diethylaminopropylaminocar-bonyl)-propyl-2-oxyJ-5-(4-methoxyphenyl)-pyrazole were mixed with 0.32 ml acetic anhydride and 0.7 ml 57~
aqueous hydroiodic acid. The mixture was heated for one hour under reflux and was then carefully added into ice-cold sodium carbonate solution and extracted exhaustively with diethyl ether. The ether extract was dried over magnesium sulphate and evaporated. The remaining crude title compound was purified by chroma-tography on silica gel (elution agent: ethyl acetate containing 15% triethylamine). 15 mg 3-r2-(3-diethyl-aminopropylaminocarbonyl)-propyl-2-oxyl-5-(4-hydroxy-phenyl)-pyrazole were obtained. IR-spectrum (as film):
3220 cm~l, 1655 cm~l, ~1530 cm-l.
The compounds of Formula I listed in the following Table can also be prepared according to the methods described in the foregoing examples. The IR-bands indicated in cm-l in the Table are the most cbaract~ristic bands of the IR-spectra of the respec-tive free bases (as film unless indicated otherwise).

Ul ~"J U~ U~
uo ~ ~r ~ r~J
~ U~ ~ U
` o ` U U~ O U~U- O U~
O U~ C~ O U) ~ ~ ` U~ U~
` ~ ) ` U'l ~ ~ ~ .
~ ~ D O ~ 1 o~ ~ ~ ~ u ~1) u~ ~ . o ~ ~ ~1 0~0~ .,~0~ 0~0-7 ~ O ~0 ~0~ 1J
rl ~ O ~ ~ O ~ ~ ~ O ,~O o .
0 ~ O ~ ~
- E ~; E - E ~ - E- E ~- E ~
I C~ I C~ `I t~ ` I ` C2 1 ~ ~~ I ~ K I K I C~ ~ ~:
--~ X ~ X c4 ~ X ~ Xca ~ ~ x ~ l a ____ _ _ _________________________ ____ ~0 ~ :C ~
n n X n X n n U I :C .
X n X n n ~ U X 3 1 --I r~ U :~: X '~ r ~ ~ I U
C2~ n U r ) , ~ I U U U 5: U U ~ n I V V
_. o U --~ G ~1 ~
~ '` n 3: X n n t n n .~ `~ ~ U V O
C~ I U U ~ U ~) ~ r~ 3 ~ r~ C IU 1' ~ ~::
____ _______________________ _______ t:O
X
~_) . . ~ ~
T . . ~ ~U
O . r~
UX 5~ X~: ~ ~
r~U5~ Xr: :C U U U U ~)n n ~d ~ -3:1,. ,. .. .. .. . I I I I I I
U~ ) U ~) U t.) U ~:: C C C C ~ ~
_ _ __ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ ,_ _ __ _ __ _ _ __ _ a3 Q) ~0 J~
. o K X X X X X U U U X X ~ X X X ~ V
____ __________________________ _____ n n r n n n n nn ~ n I O
~:r~ U ~ U V ~ U V X U VU r._) ~ ) 5 ~J
n n n n n n n n n nn n ~
~;3~ X 3: X 1~ X X ~ .,1 .,1 ~ u X U V ~Xu ~ ' u :~~ vu u u tn ~
___ _____________._~____ _________ ~
. ~ J

~: ~ X 1~ ~ I
11~
q .
. O
C2:C ~ XS: X ~ X:1: X ~ ~ ~
____ ________________________________ n O
X X
~: U ~ 11 ~
I ~ ~ bO
_ r.~ r.~ xx 3: X ~ XX ~ X ,1 o ___ ______________________________ O~
r :1: n U ~ U rv,~
___ ______ ._._____ _____________. _ ___ _ ~n ~1 U~rJ~ O ~ ~ ~ U~ ~ rr-~ , y _~ ~~ ~ ~ ~ r,~ ~ r,~l X O

o r-) o o o r~ r~ O O r,~~ r,7 r.--~ O It7 1 O O ~ rl _~ ~r~
, O O rXI 00 r.~.' O r,~J O
~ D rJJ, ~ D La D ~) O ~:1 ~D a~

, ~ ~i ~4 0 U'~ r~ r~ 0 ~1 0 r~ 'O -0 f~ ~u~ rl O
E E E É E E ~ É ~ Ea ,~ Ea ,~ ~ ~ a d ~ r ` E~ a ~ ~a ~ ~ X ~ ~ X ~ ~ X ~ ~ x ___ _____ ~

~~ n r X n :~ nn n n ~ n X n:1 ~1 t~h ~ U U U I Ul U~U U U) U O O~:

n X 3 r~n ~ ~ X~ ~ 1: X:~: X t~ .,1 ~:U U U U U I U ~U ~ U U U U ~ U~1 0 .____ _I____~_________________________ 5 ~0 U U U , .~.
I U U U X ~ C ~
U " ~ U U U~ ut ~ U n u u~ u " ~ u u :: ~ E
____ _______________________________ .
. . ~ .-. ~o ~
~ X :r: S I S X 3:: S X _X _S _~ _X_:~ _X o v ____ __---------------------------- I n n ~
~ x a: x~ 1: S ~ S ~ S~ ll ~: u u u u ~- s ~ u u u :r: u u U U u E ~o tl: n n n ~t 1 ~ r rt I n t3~
U U U ~J X ~ X U ' U S ~ ^ -~1 ____ __-~___________________ _________ rl ~ n .. ~ _ ~: 3: S ~ S ~ S X ~ ~
oX
n ~ n n n n ~1 r S x ~ ~ - ..
U U U U ~ ~U U U U U 11 ~
C~ X S :~: S ~r ~r ~r ~ ~ ~ ~ ~ -r ~ ~ ~r ~ 0 ____ _________________________-_____ ~1 r~
~: .rl~
~ 3 S S ~ X C ~ X X

____n 3 S ~ ~
~ ~ U ~ S . 5~ X X :~: U
_ _._ _ _ _ __ _ ~ _-- ~ .~.
~ 11 ~ . O ~ ~ ~ ~ ~n ~D r~ r~ ~ G ~ r ~ 0 :~
f0 1~:1 .

X ZO

u~ o ~ o ~
O ~no o o o ~ o o u, O ~e ~ ~ ~ ~~ ~ O ~ ~,~ ~
O 11~ ~ ~ O ~ - rl ~ r~ ` O
` u~ I O o O o ~ O o o o ~rl 1~ ~
a~ Ua~ "~ ~ r~ F~ O' ~ n ` ~ E ~ ~ ~ ~ .~ ~
~3 1~
r7 rl ~ ~ ~ O ~ O ~ O ~ O J O O r~ ~ 0 ~" ~u~ ~ ~ ~ ~ ~ .~ ~ ~ .~ ~ .. , E ~) ~ . E ~ E ~? U ~ E ~' E <> E0 .<~ E ~ E E E ~- E ~ ~ ~
~ ~X ~ T ~ ~ (I) rl ____ _______________________________ tlOO
, ~ ~
n n n n n ~ n n n n n ~ r r r~ I I r~ r~ u I ~ I r~ r~ r~ 1.
cl: U n ~ ) I .r u U ~ U u U 1I r n s x rl n n n .~ r n n ; n n n ~ E
.. -- ~ .,.,. "~, " " _ I a ~J u u l u u l u u u ~
~ ~ -u lu ~

t~ :~ X U:1: X ~.3: U 1: ~ al.,J
u ~ u I u Un :C UUn ~ I ù' u E~ .'!
I " " " I :r: I. I " I I " :~: I I ,.
___ ~ _ U U _U _ ~ _U ~ _ ~ _U ~ _U_U _ 1::_ C ~ ~
.. . ~o ta tr: ~ X X 3: ~: X ~ X ~ ~., ___ ____ _________________________ 11~
X X r~ n r~ n r~ n n n n X n ~ E 00 n~uuuuuuuuuuuu~uu Io nn n n n X~ X X X 1 x I n ~ r l rl u 3: :~ U u u u u ~_) u u u ~ u u ________________~________________ ~ n :~: S X X 3~ r :: ~ ~J
o o o ~ n x :~: ~ I I u ~ a U U ~ ~ ~ UU U ~ ~ I o ~
n I I I I II ~ ~ O ~Ll tll 1~: ~ ~ ~ ~ ~ ~~ q ~) I X X ~ ).1 --~ -o ~
~ XX S~ X 3~ 11 ~0 C~ U ~ ~ X :C X U ~ O ,~:
a~ . .D ~
_~ ~ 0 ~ ~r~ D l~ ~ ~ O ll l X ;o --3 8--Z;

5~

o ~7 ~ ~ o In o o _ ~`J

` rJ `~ U~ .~1 `~ ` o ~ `
o ~0 'O O rl 1~ `.D o O ' It`) ~ ~ 1 . O O U'~ O U') '1 o ~ 1~ ~
~ ~ ~ ~ ~ o ~ ~- ~ ~ ...
V~ ~ ~ r~ ~ ~I) r-l O ~r~ O ~ O ~ O O ,_~ O ~ o ~ O ~ ol--l o ~
~, .,, .,, U'~ O ~ ~e, O O ~, ,, r~-,J _ td 0~ ~ O ~ 1~ 0~ ~ ~ ~ ~ ~
a) 0 ~ O <> ~ r( 0 ~ 0 ~ 0 1~
~; E - ~ - E - E - - E - ~ - E~ E - E - E ~- E - ~d ' ~: ~
n n n ~ U ~ n L~ U lJ U U O U U U U n U U t_) 3 n n n :~: n ~ n 5 ~ ~ n 1~ 1 ____ U U U U I U U U U 1 3: ~ U U V O

U 1_~ . O .r~
I :~ ' . v.LJ
O O , o ~ E
n r I I n n n n ~ n n ,J ~1 __._ ~ U U 1~ _L _ E :~:
aJ
. ~o _ o n 3: n n n ~ n n n X ~ 5: ~ a) ~: ~ u ~ u u u u U u u u u ,E ~0 . n 1: 5-1 n ~ n n ~ n ~ n , n n X S ~) n . ~ ~, :2: ~ S S X :I: S :~ , ,~
U ~ U U U U U U ~- U ~ ~: U r ____ __________________.__________ .
~ 11 Ci: S :~: ~ X S ~ C ~ X ~ ~'t) . ~ X
:;: ' ' ~_ ____ ~ 5 ~ X ~ X 1 ~ X ~ X :r: S o n~) ~ ~n n U I U
~: ~ l U U l_J t_) C U O ~

~ t t`J ~ I _ _ S _ ~ _ 1~0 ____ ______________ ______ ~10 Cl: S ~ Z I X x ~a ___ _________~_ ________________ aJ ~ ~ o _-X zO _ 3 9 _ The invention is further illustrated by the following Example of a pharmaceutical composition.
Example I: Tablets Tablets are produced with the following com-position per tablet:
3-t2-(3-diethylaminopropylaminocarbonyl)-propyl-2-oxyl-5-phenylpyrazole-hydrogen maleinate 15 mg Maize starch 60 mg Lactose 140 mg Gelatine (as 10% solution) 6 mg The active substance, the maize starch and the lactose are thickened with the 10~ gelatine solution. The paste is comminuted and the resulting granulate is deposited onto a suitable metal sheet and driedO The dried granulate is guided through a crushing machine and mixed in a mixer with the following further adju-vant substances:
Talcum ~ 5 mg Magnesium stearate 5 mg 20 Maize starch 9 mg and then compressed to 240 mg tablets.
The foregoing description has been set forth merely to illustrate the invention and is not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the scope of the invention is to be limited solely with respect to the appended claims and equivalents.

Claims (24)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:-

1. A process for the preparation of a 3-aminocarbonylmethoxy-5-phenylpyrazole compound corresponding to the Formula I:

I

wherein R1 is hydrogen or lower alkyl, R2 is in position 1 or 2 on the pyrazole ring and is hydrogen or lower alkyl, R3 is hydrogen, halogen, lower alkyl or lower alkoxy and R4 is hydrogen, halogen, lower alkyl, lower alkoxy or, if R3 is hydrogen, R4 may also be trifluoro-methyl, nitro or hydroxy or R3 and R4 are linked to two adjacent carbon atoms and together represent an alkylene dioxy group with 1 or 2 carbon atoms.
R5 is hydrogen or lower alkyl and R6 is hydrogen or methyl or R5 and R6 together form an alkylene chain with 3 to 5 carbon atoms, R7 is hydrogen or lower alkyl, Z is an alkylene chain with 2 to 5 carbon atoms or the 2-hydroxypropylene chain, R8 is hydrogen or lower alkyl and R9 is hydrogen or lower alkyl or R8 and R9 together with the nitrogen atom to which they are linked represent a heterocyclic group corresponding to the Formula a:

a wherein A is an alkylene chain with 4 or 5 carbon atoms which chain may be substituted by 1 or 2 methyl groups, or A is the -C2H4-O-C2H4-chain, or if Z is an alkylene chain, then R8 may be hydrogen or lower alkyl and R9 may be an alkylene chain which together with the nitrogen atom to which it is linked and the carbon atom of the alkylene chain Z which is adjacent to this nitrogen atom, forms a 5- or 6-membered heterocycle, and its acid addition salts, characterized in that a) a compound corresponding to Formula II or Formula III:

II III

in which R1, R2, R3, R4, R5 and R6 have the above defined meanings and Y is a reactive group, is reacted with a compound corresponding to the Formula VIII:

VIII

in which R7, Z, R8 and R9 have the above defined meanings, or b) a compound corresponding to the Formula IV:

IV
in which R1, R2, R3, R4, R5, R6, R7 and Z have the above defined meanings and X is a group which can be split off aminolytically is reacted with an amino com-pound corresponding to the Formula V:

V

in which R8 and R9 have the above defined meanings, or c) a compound corresponding to the Formula VI:

VI
in which R1, R2, R3 and R4 have the above defined meanings, a 5-phenylpyrazolin-3-one compound tautomeric therewith, or a mixture thereof is reacted with a com-pound corresponding to the Formula VII:

VII

in which R5, R6, R7, Z, R8 have the above defined meanings and Hal is halogen, or d) for the preparation of a compound corresponding to the Formula Ia:

Ia in which R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the above defined meanings, a compound corresponding to the Formula IX:

IX
in which R1, R2, R3, R4, R5, R6 and R7 have the above defined meanings, is reacted with a compound corresponding to the Formula V, and in the case wherein R4 is methoxy, optionally further comprising the step of reacting the methoxy group with a suitable reagent in a suitable solvent to form a hydroxy group, and in the case wherein said compound corresponding to Formula I is obtained in the form of a free base, optionally further comprising the step of converting the free base to a pharmacologically accep-table acid addition salt, and in the case wherein said compound corresponding to Formula I is obtained in the form of an acid addition salt, optionally further comprising the step of converting the acid addition salt to a free base.

2. A process according to Claim 1, wherein R1 is hydrogen or alkyl with l or 2 carbon atoms and R2 is hydrogen or methyl.

3. A process according to Claim 1, wherein R5 and R6 together have 3 carbon atoms.

4. A process according to Claim 1, wherein R5 and R6 are each methyl or R5 is alkyl with 1 to 3 carbon atoms and R6 is hydrogen.

5. A process according to Claim 1, wherein R8 is hydrogen or alkyl with 1 or 2 carbon atoms and R9 is hydrogen or alkyl with 1 or 2 carbon atoms;
or R8 and R9 together with the nitrogen atom to which they are linked, represent a pyrrolidine, piperi-dine or morpholine ring; or R8 is hydrogen or methyl and R9 together with the nitrogen atom and the carbon atom of the alkylene chain Z adjacent thereto represents a pyrrolidine ring.

6. A process according to Claim 1, wherein R1 is hydrogen or alkyl with 1 or 2 carbon atoms, R2 is hydrogen or methyl, R3 is hydrogen, halogen, methoxy or methyl, R4 is hydrogen, halogen, methoxy or methyl, R5 and R6 are each methyl, R7 is hydrogen, Z is an alkylene chain with 2 to 4 carbon atoms or the 2-hydroxypropylene chain, and R8 is hydrogen or alkyl with 1 or 2 carbon atoms and R9 is alkyl with 1 or 2 carbon atoms or R8 and R9 together with the nitrogen atom to which they are linked form a pyrrolidine or piperidine ring.

7. A process according to Claim 6, wherein R1 is hydrogen or methyl.

8. A process according to Claim 6, wherein Z is an alkylene chain with 3 or 4 carbon atoms or the 2-hydroxypropylene chain.

9. A process according to Claim 6, wherein R1 is an alkyl group with 1 or 2 carbon atoms, and Z is an ethylene chain.

10. A process according to Claim 6, wherein R8 and R9 are each alkyl with 1 or 2 carbon atoms or R8 and R9 together with the nitrogen atom to which they are linked form a pyrrolidine or piperidine ring.

11. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound corresponding to the Formula I:

wherein R1 is hydrogen or lower alkyl, R2 is in position 1 or 2 on the pyrazole ring and is hydrogen or lower alkyl, R3 is hydrogen, halogen, lower alkyl or lower alkoxy, and R4 is hydrogen, halogen, lower alkyl, lower alkoxy, or, if R3 is hydrogen, R4 may also be trifluoro-methyl, nitro or hydroxy, or R3 and R4 are linked to two adjacent carbon atoms and together represent an alkylene dioxy group with 1 or 2 carbon atoms, R5 is hydrogen or lower alkyl, and R6 is hydrogen or methyl, or R5 and R6 together form an alkylene chain with 3 to 5 carbon atoms, R7 is hydrogen or lower alkyl, Z is an alkylene chain with 2 to 5 carbon atoms or the 2-hydroxypropylene chain, R8 is hydrogen or lower alkyl, and R9 is hydrogen or lower alkyl, or R8 and R9 together with the nitrogen atom to which they are linked represent a heterocyclic group corresponding to the Formula a:

a wherein A is an alkylene chain with 4 or 5 carbon atoms which chain may be substituted by 1 or 2 methyl groups, or A is the -C2H4-O-C2H4-chain, or if Z is an alkylene chain, then R8 may be hydrogen or lower alkyl, and R9 may be an alkylene chain which together with the nitrogen atom to which it is linked and the carbon atom of the alkylene chain Z which is adjacent to this nitrogen atom, forms a 5- or 6-membered heterocycle, and its acid addition salts.

12. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 11, wherein R1 is hydrogen or alkyl with 1 or 2 carbon atoms, and R2 is hydrogen or methyl.

13. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 11, wherein R5 and R6 together have 3 carbon atoms.

14. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 11, wherein R5 and R6 are each methyl or R5 is alkyl with 1 to 3 carbon atoms and R6 is hydrogen.

15. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 11, wherein R8 is hydrogen or alkyl with 1 or 2 carbon atoms and R9 is hydrogen or alkyl with 1 or 2 carbon atoms;
or R8 and R9 together with the nitrogen atom to which they are linked, represent a pyrrolidine, piperi-dine or morpholine ring; or R8 is hydrogen or methyl and R9 together with the nitrogen atom and the carbon atom of the alkylene chain Z adjacent thereto represents a pyrrolidine ring.

16. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 11, wherein R1 is hydrogen or alkyl with 1 or 2 carbon atoms, R2 is hydrogen or methyl, R3 is hydrogen, halogen, methoxy or methyl, R4 is hydrogen, halogen, methoxy or methyl, R5 and R6 are each methyl, R7 is hydrogen, Z is an alkylene chain with 2 to 4 carbon atoms or the 2-hydroxypropylene chain, and R8 is hydrogen or alkyl with 1 or 2 carbon atoms and R9 is alkyl with 1 or 2 carbon atoms or R8 and R9 together with the nitrogen atom to which they are linked form a pyrrolidine or piperidine ring.

17. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 16, wherein R1 is hydrogen or methyl.

18. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 16, wherein Z is an alkylene chain with 3 or 4 carbon atoms or the 2-hydroxypropylene chain.

19. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 16, wherein R1 is an alkyl group with 1 or 2 carbon atoms, and Z is an ethylene chain.

20. A 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 16, wherein R8 and R9 are each alkyl with 1 or 2 carbon atoms or R8 and R9 together with the nitrogen atom to which they are linked form a pyrrolidine or piperidine ring.

21. 3-[2-(3-diethylaminopropylaminocarbonyl)-propyl-2-oxy]-5-phenylpyrazole as defined in Claim 11 and its acid addition salts.

22. 3-[2-(3-diethylamino-2-hydroxypropyl-aminocarbonyl)-propyl-2-oxy]-5-phenylpyrazole as defined in Claim 11 and its acid addition salts.

23. 3-[1-(2-pyrrolidinoethylaminocarbonyl)-propyl-1-oxy]-5-(4-chlorophenyl)-pyrazole as defined in Claim 11 and its acid addition salts.

24. An antiarrrhythmic pharmaceutical composition containing an antiarrhythmically effective quantity of a 3-aminocarbonylmethoxy-5-phenylpyrazole compound as defined in Claim 11 and at least one additional substance selected from the group consisting of conventional pharmaceutical adjuvants and carriers.